This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2002 Nov;144(5 Suppl):S8-11.

doi: 10.1067/mhj.2002.129971.

New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone

John W Funder¹

Affiliations

Affiliation

¹ Centre for Neurosciences, University of Melbourne and Prince Henry's Institute of Medical Research, Monash Medical Centre, Victoria, Australia. susan.smith@med.monash.edu.au

PMID: 12422135
DOI: 10.1067/mhj.2002.129971

Review

New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone

John W Funder. Am Heart J. 2002 Nov.

. 2002 Nov;144(5 Suppl):S8-11.

doi: 10.1067/mhj.2002.129971.

Author

John W Funder¹

Affiliation

¹ Centre for Neurosciences, University of Melbourne and Prince Henry's Institute of Medical Research, Monash Medical Centre, Victoria, Australia. susan.smith@med.monash.edu.au

PMID: 12422135
DOI: 10.1067/mhj.2002.129971

No abstract available

PubMed Disclaimer

Similar articles

Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Hu X, Li S, McMahon EG, Lala DS, Rudolph AE. Hu X, et al. Mini Rev Med Chem. 2005 Aug;5(8):709-18. doi: 10.2174/1389557054553811. Mini Rev Med Chem. 2005. PMID: 16101407 Review.
Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD, Nawarskas JJ, Anderson JR. Moore TD, et al. Heart Dis. 2003 Sep-Oct;5(5):354-63. doi: 10.1097/01.hdx.0000089783.30450.cb. Heart Dis. 2003. PMID: 14503934 Review.
[Aldosterone antagonist therapy for chronic heart failure].
Yamamoto T, Yano M. Yamamoto T, et al. Nihon Naika Gakkai Zasshi. 2005 Feb 10;94(2):262-9. doi: 10.2169/naika.94.262. Nihon Naika Gakkai Zasshi. 2005. PMID: 15768590 Review. Japanese. No abstract available.
Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL. Endemann DH, et al. Hypertension. 2004 Jun;43(6):1252-7. doi: 10.1161/01.HYP.0000128031.31572.a3. Epub 2004 Apr 26. Hypertension. 2004. PMID: 15117913
Aldosterone target organ protection by eplerenone.
Rudolph AE, Rocha R, McMahon EG. Rudolph AE, et al. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):229-38. doi: 10.1016/j.mce.2003.10.047. Mol Cell Endocrinol. 2004. PMID: 15134822 Review.

See all similar articles

Cited by

ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression?
Bakris GL. Bakris GL. J Clin Hypertens (Greenwich). 2007 Jun;9(6):413-5. doi: 10.1111/j.1524-6175.2007.07234.x. J Clin Hypertens (Greenwich). 2007. PMID: 17541325 Free PMC article. No abstract available.
Aldosterone: good guy or bad guy in cerebrovascular disease?
Rigsby CS, Cannady WE, Dorrance AM. Rigsby CS, et al. Trends Endocrinol Metab. 2005 Nov;16(9):401-6. doi: 10.1016/j.tem.2005.09.002. Epub 2005 Oct 6. Trends Endocrinol Metab. 2005. PMID: 16213743 Free PMC article. Review.
Mineralocorticoid-receptor blockade in hypertensive patients during angiotensin-converting enzyme inhibition: effects on left ventricular mass.
Carey RM, Logan AG. Carey RM, et al. Curr Hypertens Rep. 2004 Apr;6(2):113-4. Curr Hypertens Rep. 2004. PMID: 15010013 No abstract available.
Neuroendocrine humoral and vascular components in the pressor pathway for brain angiotensin II: a new axis in long term blood pressure control.
Hamlyn JM, Linde CI, Gao J, Huang BS, Golovina VA, Blaustein MP, Leenen FH. Hamlyn JM, et al. PLoS One. 2014 Oct 2;9(9):e108916. doi: 10.1371/journal.pone.0108916. eCollection 2014. PLoS One. 2014. PMID: 25275393 Free PMC article.
Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
Yang P, Shen W, Chen X, Zhu D, Xu X, Wu T, Xu G, Wu Q. Yang P, et al. Heart Fail Rev. 2019 Sep;24(5):637-646. doi: 10.1007/s10741-019-09790-5. Heart Fail Rev. 2019. PMID: 31030322

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.